Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114150 | 0.92 | DRD2 (0.64) | DRD2HTR1AHTR2ADRD3 | |
| SCHEMBL12403673 | 0.87 | LMNA (0.72) | LMNAKDM4EDRD2HTR1AHTR2A | |
| SCHEMBL2002856 | 0.87 | DRD2 (0.55) | HRH3LMNAKDM4EDRD2HTR1A | |
| Hydrochloric Acid SCHEMBL1114457 | 0.86 | LMNA (0.74) | LMNAKDM4EDRD2HTR1AHTR2A | |
| SCHEMBL12403727 | 0.85 | HRH3 (0.62) | HRH3LMNAKDM4EDRD2HTR1A | |
| SCHEMBL2001553 | 0.83 | DRD2 (0.57) | DRD2HTR1AHTR2AALDH1A1 | |
| SCHEMBL1780938 | 0.81 | DRD2 (0.57) | LMNAKDM4EDRD2HTR1AHTR2A | |
| SCHEMBL2004136 | 0.80 | DRD2 (0.65) | DRD2HTR1AHTR2A | |
| SCHEMBL22417421 | 0.79 | HRH3 (0.56) | HRH3LMNAKDM4EDRD2HTR1A | |
| SCHEMBL4235263 | 0.78 | DRD2 (0.51) | LMNAKDM4EDRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279179-B1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2014-09-17 | — | — | EP | claimed |
| US-8772299-B2 | Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-07-08 | — | — | US | claimed |
| CN-102046610-B | Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof | SK HOLDINGS CO LTD | 2013-06-05 | — | — | CN | claimed |
| US-7985752-B2 | Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-07-26 | — | — | US | claimed |
| US-20110118264-A1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-05-19 | — | — | US | claimed |
| CN-102046610-A | Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof | SK HOLDINGS CO LTD | 2011-05-04 | — | — | CN | claimed |
| EP-2279179-A2 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2011-02-02 | — | — | EP | claimed |
| US-20090298831-A1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-12-03 | — | — | US | claimed |
| WO-2009145591-A2 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2009-12-03 | — | — | WO | claimed |
| EP-2279179-B1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2014-09-17 | — | — | EP | disclosed |
| EP-2279179-B1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2014-09-17 | — | — | EP | disclosed |
| US-8772299-B2 | Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-07-08 | — | — | US | disclosed |
| US-8772299-B2 | Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-07-08 | — | — | US | disclosed |
| US-8772299-B2 | Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-07-08 | — | — | US | disclosed |
| EP-2279179-A2 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2011-02-02 | — | — | EP | disclosed |
| US-20090298831-A1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-12-03 | — | — | US | disclosed |
| US-20090298831-A1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-12-03 | — | — | US | disclosed |
| US-20090298831-A1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-12-03 | — | — | US | disclosed |
| WO-2009145591-A2 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009145591-A2 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298831-A1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF | HTR5A, HTR1A, HTR2A | HRH3 299/4885LMNA 2733/4885KDM4E 2044/4885 |
| US-20110118264-A1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF | HTR5A, HTR1A, HTR2A | HRH3 299/4885LMNA 2590/4885KDM4E 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.